ESSA Pharma Announced Data Combination Of Masofaniten Plus Enzalutamide Continues To Be Well Tolerated With Deep And Durable Reductions In PSA In Patients With Metastatic Castration-Resistant Prostate Cancer
Portfolio Pulse from Charles Gross
ESSA Pharma Inc. (NASDAQ:EPIX) has announced updated dose escalation data from its Phase 1/2 study evaluating masofaniten in combination with enzalutamide for the treatment of prostate cancer. The data, presented at the ESMO 2023 Congress, shows that the combination is well tolerated and results in significant reductions in prostate-specific antigen (PSA) in patients with metastatic castration-resistant prostate cancer (mCRPC). Across all cohorts, 69% of patients achieved PSA90, 63% achieved PSA90 in less than 90 days, and 56% achieved PSA <0.2mg/mL.
October 21, 2023 | 1:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ESSA Pharma's updated data from its Phase 1/2 study shows promising results for the treatment of prostate cancer, which could potentially boost investor confidence and the company's stock price.
The positive results from ESSA Pharma's Phase 1/2 study indicate that the company's treatment for prostate cancer is effective and well-tolerated. This could lead to increased investor confidence in the company's ability to develop successful treatments, potentially leading to an increase in the company's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100